Skip to main content
Premium Trial:

Request an Annual Quote

Make Way for CalIBR

Merck this week launched the California Institute for Biomedical Research, or CalIBR, "a new nonprofit research institute to help academics turn their basic biology insights into drug compounds ready for human tests," Science reports, adding that the pharmaceutical company is contributing $42 million over the first three years, and possibly as much as $90 million over the first seven years, to the institute. The Wall Street Journal adds that CalIBR "will be free to seek alternative funding sources for any projects not licensed by Merck and it plans to access funds from government and non-government sources" and that "revenue derived from licenses will be shared between CalIBR and the collaborating institutions."

The institute will be led by the Scripps Research Institute's Peter Schultz and "will offer academic scientists, around the world, a streamlined, efficient and flexible path for translating their biomedical research into novel medicines," according to a CalIBR statement.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.